Skip to main content
Ascletis Pharma Inc. logo

Ascletis Pharma Inc. — Investor Relations & Filings

Ticker · 1672 ISIN · KYG0520K1094 LEI · 254900SKEFCO9I3GPL05 HKEX Manufacturing
Open in API
Filings indexed 1,470 across all filing types
Latest filing 2024-12-04 Transaction in Own Shar…
Country KY Cayman Islands
Listing HKEX 1672

About Ascletis Pharma Inc.

http://www.ascletis.com

Ascletis Pharma Inc. is a fully integrated, R&D driven biotechnology company dedicated to the development and commercialization of potential best-in-class and first-in-class therapeutics. The company covers the entire value chain from discovery to sales. Ascletis primarily focuses on metabolic diseases, including chronic weight management, utilizing proprietary platforms such as Artificial Intelligence-assisted Structure-Based Drug Discovery (AISBDD), Ultra-Long-Acting Platform (ULAP), and Peptide Oral Transport ENhancement Technology (POTENT). Key pipeline candidates include ASC30 (oral/subcutaneous GLP-1R agonist), ASC35 (GLP-1R/GIPR dual agonist), ASC36 (amylin receptor agonist), and ASC37 (GLP-1R/GIPR/GCGR triple agonist). The company also maintains active programs in viral diseases, NASH/PBC, and oncology.

Recent filings

Filing Released Lang Actions
Next Day Disclosure Return
Transaction in Own Shares Classification · 95% confidence The document is a Next Day Disclosure Return (Form FF305) pursuant to the Hong Kong Stock Exchange listing rules, detailing changes in issued and treasury shares and reporting on-market share repurchases (including number of shares, prices, aggregate price paid, repurchase mandate details, etc.). This is a company’s report of buying back its own shares. According to the taxonomy, this falls squarely under “Transaction in Own Shares” (Code: POS).
2024-12-04 English
Next Day Disclosure Return
Transaction in Own Shares Classification · 90% confidence The document is a Hong Kong Exchange FF305 Next Day Disclosure Return detailing changes in issued shares, treasury shares and a repurchase report (on-market share buyback data). This clearly corresponds to the company’s transactions in its own shares (share repurchases). Therefore it fits the “Transaction in Own Shares” category.
2024-12-03 English
CHANGE OF HONG KONG SHARE REGISTRAR AND TRANSFER OFFICE
Regulatory Filings Classification · 87% confidence The document is a formal announcement by a listed Hong Kong company regarding the administrative change of its Hong Kong branch share registrar and transfer office. It is not an AGM material, financial report, management change, dividend notice, capital transaction, or other specific category. Therefore, it falls into the general regulatory announcement/fallback category.
2024-12-02 English
Monthly Return of Equity Issuer on movements in Securities for the month ended 30 November 2024
Regulatory Filings Classification · 85% confidence The document is a standardized monthly return (Form FF301) filed by a Hong Kong–listed issuer to report movements in share capital, issued shares, treasury shares, and share option details under the Exchange Listing Rules. It is neither a standalone financial report nor an announcement of an AGM or dividend, but a routine regulatory filing. It does not fit specialized categories like share issue press release (SHA) or report publication announcement (RPA), so it falls into the general Regulatory Filings category.
2024-12-02 English
Next Day Disclosure Return
Transaction in Own Shares Classification · 90% confidence The document is an FF305 Next Day Disclosure Return filed on the Hong Kong Stock Exchange detailing the company’s repurchases of its own shares, changes in issued shares and treasury shares, and an on-market sale of treasury shares. This is a report of transactions in the issuer’s own shares rather than an earnings release, dividend notice, or management discussion. It fits the definition of a Transaction in Own Shares.
2024-12-02 English
Monthly Return of Equity Issuer on Movements in Securities for the month ended 30 November 2024
Regulatory Filings Classification · 90% confidence The document is a mandated monthly return (Form FF301) filed to HKEX under Chapter 19B, detailing movements in share capital, issued shares, treasury shares, options, repurchases, etc. It is a routine regulatory submission rather than a standalone capital-raising announcement or a specific transaction notice. It does not constitute an earnings release, AGM materials, proxy statement, or full financial report. It is best classified under the general “Regulatory Filings” fallback category (RNS).
2024-12-02 English

Browse filings by year

28 years

Report missing filing

Can't find a specific document? Let us know and we'll add it within 24 hours.

We will notify you once the filing is added.
Report sent
Thank you. We will check the data and update it shortly.